LMLN2

Model summary

A human endopeptidase that operates as a secreted matrix-acting protease with an intracellular isoform pool. Its proteolytic core enables cleavage of pericellular substrates and transient docking to signaling receptors, thereby tuning extracellular cues and adhesion that influence organ laterality, including the heart. The enzyme is likely produced as a zymogen and activated outside the cell to remodel local signaling environments, while a cytosolic isoform may regulate its maturation and trafficking.

Predicted Gene Ontology terms

1. 01

   I begin with the domain architecture.

   The sequence contains IPR001577 (Peptidase M8, leishmanolysin family) spanning residues 94–774. This long M8 metalloprotease core defines a zinc-dependent endopeptidase fold characteristic of leishmanolysins and related ADAMTS-like proteases. The N-terminal boundary of the catalytic region at residue 94 implies an upstream signal sequence and prodomain that typically govern secretion and zymogen control in this family. The extensive M8 core dictates endopeptidase chemistry and substrate engagement surfaces that often mediate receptor or matrix binding.

2. 02

   This architecture causes endopeptidase activity.

   The M8 fold supports GO:0004175 endopeptidase activity and, mechanistically, GO:0004222 metalloendopeptidase activity through a metal-coordinated catalytic center that cleaves extracellular or pericellular substrates. The same scaffold frequently presents exosites for macromolecular recognition; such surfaces rationalize GO:0005102 signaling receptor binding by enabling transient docking to membrane receptors or their extracellular domains during substrate capture or signaling modulation.

3. 03

   From this catalytic and binding foundation, I infer the biological role.

   Endopeptidase-driven remodeling of pericellular matrices and receptors can tune morphogen gradients and cell–matrix adhesion that instruct organ laterality. Such proteolytic control provides a causal route into GO:0061371 determination of heart left/right asymmetry: selective cleavage of extracellular cues and adhesion complexes can bias asymmetric signaling fields essential for cardiac laterality.

4. 04

   Cellular placement follows from the domain logic and isoform behavior.

   The presence of a secreted, matrix-acting M8 protease core argues for extracellular deployment, consistent with a secreted enzyme that operates in the pericellular space. At the same time, an intracellular isoform lacking secretion signals can remain soluble and cytosolic; this supports GO:0005829 cytosol and aligns with observations that some family members shuttle between compartments or serve intracellular regulatory pools. Thus, I expect dual localization: a secreted/pericellular protease and a cytosolic isoform that may regulate trafficking or maturation.

5. 05

   Mechanistically, I hypothesize that the enzyme is produced as a zymogen whose M8 core is activated extracellularly to cleave matrix and receptor-associated substrates, thereby shaping signaling landscapes that influence cardiac laterality.

   The cytosolic isoform may modulate this pathway by controlling intracellular trafficking or assembly of the secreted protease. Likely interaction partners include cell-surface signaling receptors and extracellular matrix components that present cleavage sites and docking surfaces; transient complexes with these targets would couple proteolysis to receptor binding and pathway tuning.